HEALTHJun 7 · 11:00 UTCSCMP CHINAJulie Zhang

Which company could become the Chinese Pfizer? Here are analysts’ top picks

Chinese biotechnology companies are projected to market their own medications in Europe and the US within 10 to 15 years, according to analysts. Discussions among investors and analysts focus on identifying which firms will achieve international sales amid a boom in outlicensing agreements.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Chinese biotechnology companiesorganizationEuropeplaceUSplaceoutlicensing agreementstopicPfizertopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSJun 7 · 11:00 UTC
Which company could become the Chinese Pfizer? Here are analysts’ top picks
BUSINESSJun 3 · 11:06 UTC
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
BUSINESSMay 26 · 08:20 UTC
Hong Kong-Listed Biotech Insilico Is Said to Explore UAE Listing
BUSINESSMay 5 · 17:22 UTC
Robinhood Just at Beginnings of Prediction Markets, CEO Tenev Says
BUSINESSMay 6 · 06:18 UTC
Novo Raises Forecast as Wegovy Pill Fuels Sales
BUSINESSMay 1 · 15:16 UTC
Leo Pharma Is Said to Add More Banks to Copenhagen IPO Lineup